IMMUNOENDOCRINE DISTURBANCES IN PATIENTS WITH SCHIZOPHRENIA IN THE PROCESS OF ANTIPSYCHOTIC THERAPY

封面

如何引用文章

全文:

详细

Study of dynamics of immunoendocrine parameters in 27 patients with schizophrenia has shown that acute period of schizophrenia after long-term maintenance treatment with quetiapine is accompanied by immune-hormonal imbalance characterized by cellular immune deficit, increase in the concentration thyroid-stimulating hormone, reduction in thyroid hormones and prolonged elevation of the level of cortisol in blood. The obtained data will allow further revealing the criteria of personalized approach to treatment of patients with possible joining additional pharmacotherapy from the first days of the admission of patients in the hospital.

作者简介

O. Lobacheva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Mental Health Research Institute of Tomsk NRMC)

编辑信件的主要联系方式.
Email: oalobacheva@mail.ru

MD, lead researcher of the Laboratory of Clinical Psychoneuroimmunology and Neurobiology, 

Tomsk

俄罗斯联邦

T. Vetlugina

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Mental Health Research Institute of Tomsk NRMC)

Email: fake@neicon.ru

D. Sc., Prof., lead researcher of the Laboratory of Clinical Psychoneuroimmunology and Neurobiology, Head of the Department of Biological Psychiatry and Narcology,

Tomsk

俄罗斯联邦

E. Kornetova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Mental Health Research Institute of Tomsk NRMC)

Email: fake@neicon.ru

MD., lead researcher of the Endogenous Disorders Department,

Tomsk

俄罗斯联邦

A. Semke

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Mental Health Research Institute of Tomsk NRMC)

Email: fake@neicon.ru

MD., Prof., Head of the Endogenous Disorders Department,

Tomsk

俄罗斯联邦

参考

  1. Теоретические и практические аспекты психонейроэндокринологии. / Под ред. проф. Л. Н. Горобец. М.: 2012, 40–57.
  2. Müller N. Immunological aspects of the treatment of depression and schizophrenia. Dialogues Clin Neurosci. 2017, 19(1), 55–63.
  3. Никитина В. Б., Лобачева О. А., Ветлугина Т. П., Аксенов М. М., Лебедева В. Ф. Нейроиммуноэндокринные нарушения при психических расстройствах и болезнях зависимости. Сибирский вестник психиатрии и наркологии. 2018, 2(99), 45–55.
  4. Мосолов С. Н., Цукарзи Э. Э., Капилетти С. Г. Антипсихотическая фармакотерапия шизофрении: от научных данных к клиническим рекомендациям. В кн.: Биологические методы терапии психических расстройств / Ред. Мосолов С. Н. Доказательная медицина – клинической практике. Москва, 2012, 11–61.
  5. Ветлугина Т. П., Лобачева О. А., Альперина Е. Л., Жукова Е. Н., Семке А. В., Никитина В. Б., Чейдо М. А., Идова Г. В. Клинико-экспериментальные исследования иммуномодулирующего эффекта амисульприда. Вестник Российской академии медицинских наук. 2012, 12(67), 13–17.

版权所有 © Lobacheva O.A., Vetlugina T.P., Kornetova E.G., Semke A.V., 2019

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##